KR20190042164A - Composition and method for non-atiseptic wet tissues containing the ingredient to inhibit microbial propagation - Google Patents

Abstract

The present invention relates to a non-antiseptic wet tissue composition containing ingredients inhibiting microbial propagation and a preparation method thereof. The non-antiseptic wet tissue composition comprises 0.15 to 0.4 part by weight of isopentyldiol, 0.25 to 0.4 part by weight of propanediol, 0.12 to 0.25 part by weight of caprylhydroxamic acid, 0.01 to 0.08 part by weight of octyldodeceth-16, 0.15 to 0.4 part by weight of 1,2-hexanediol, 0.1 to 0.2 part by weight of ethylhexylglycerin, and 0.001 to 0.01 part by weight of a complex extract with respect to 99 parts by weight of purified water. Therefore, the non-antiseptic wet tissue composition has an effect of reducing side effects although the composition is used in sensitive skin by using ingredients with high stability. Further, the non-antiseptic wet tissue composition not only has high bactericidal properties, but also inhibits microbial propagation and prevents decomposition, while enabling a user to use the composition with an easy mind even when residues are remained on sensitive oral cavity, skin and the like as well as infants and women.

Description

BACKGROUND OF THE INVENTION 1. Field of the Invention [0001] The present invention relates to a composition for a wetted wipes containing a component inhibiting microbial propagation and a method for producing the composition.

The present invention relates to a composition for a no-opportune side wet tissue containing a component inhibiting microbial propagation and a method for producing the same, and more particularly, to a composition for a wet tissue, which can enhance a preservative function, an antibacterial function and a stability by using a harmless preservative component And a method for producing the same. BACKGROUND OF THE INVENTION

2. Description of the Related Art Recently, wipes are divided into cleaning, oral, and hygienic applications. As the use of wipes for women, infants, and the like is diversified, the types of wipes are diversifying and demand is increasing.

Since these products are used while being carried, they are prevented from corruption by using chemical substances such as preservatives and preservatives in order to prevent microbial propagation, component denaturation or decay that may occur due to exposure to the outside air, etc., There is a problem that chemical components remain on the skin because they are not separately washed with water.

Generally, preservatives such as parabens, imidazolidinyl urea, isopropyl alcohol, formaldehyde, and paraffin used in cosmetics and skin are low in raw material costs, while using such preservatives in the long term, they cause endocrine disruption, And the like, so that consumers are reluctant to use a product containing a preservative.

In particular, since the wet tissue for infants and children is often used to wipe away the skin or mouth of children or simply remove the foreign material when going out, the use of the wet tissue containing the preservative may result in a weak immune system, In addition to reducing burns and cell membrane damage, serious problems can arise that could cause serious damage to the organ.

Related prior arts are disclosed in Korean Patent Publication No. 10-2017-0009702 entitled " preservative composition comprising tropolone and a wet tissue including the same, published on Jan. 25, 2017, 2017-0087319 (the name of the invention: a wet tissue containing a mackerel component and a manufacturing method thereof, public date: Jul. 28, 2017).

Disclosure of Invention Technical Problem [8] Accordingly, the present invention has been made keeping in mind the above problems occurring in the prior art, and an object of the present invention is to provide a composition for suppressing microbial propagation in a composition for a wet tissue, which can enhance a preservative function, And a method for producing the same.

Other objects, features and advantages of the present invention will become apparent from the following detailed description of the present invention when taken in conjunction with the accompanying drawings.

In order to achieve the above object, the present invention has the following technical features.

The composition for unsupplemented wet wipes according to the present invention contains 0.15 to 0.4 parts by weight of isopentyldiol, 0.25 to 0.4 part by weight of propanediol, 0.1 to 4 parts by weight of caprylic hydroxamic acid, 0.12 to 0.25 parts by weight of an acid, 0.01 to 0.08 parts by weight of octyldodeces-16, 0.15 to 0.4 parts by weight of 1,2-hexanediol, 0.1 to 0.2 parts by weight of ethylhexyl glycerin, and 0.001 to 0.01 part by weight of a combined extract .

In the composition for an unsuppressed wet tissue containing a component for inhibiting the growth of microorganisms according to the present invention, the isopentyldiol has a technical feature that can be replaced by butylene glycol.

The composition of the present invention includes a purified water, a rooibos leaf extract, an oat leaf extract, an aloe vera leaf extract, an olive leaf extract, a green tea extract, an isopentyl Diols, 1,2-hexanediol, and the like.

The method for preparing a composition for a no-buoyant wet tissue containing a component for inhibiting the growth of microorganisms according to the present invention comprises mixing 0.15 to 0.40 parts by weight of isopentyldiol and 0.25 to 0.4 parts by weight of propanediol based on 99 parts by weight of purified water, 0.12 to 0.25 part by weight of caprylic hydroxamic acid is mixed and heated to 50 to 60 캜; Adding 0.01 to 0.08 part by weight of octyldodeceth-16 dissolved in the mixture heated in the heating step; 0.15 to 0.4 parts by weight of 1,2-hexanediol and 0.1 to 0.2 parts by weight of ethylhexyl glycerin are added to the mixture, and the mixture is cooled to 35 to 40 DEG C; And a stirring step of gradually adding 0.001 to 0.01 part by weight of the complex extract to the mixture after the cooling step and stirring for 8 minutes to 12 minutes.

In the method for preparing a composition for unsupervised wet wipes containing a component for inhibiting the growth of microorganisms according to the present invention, the isopentyldiol mixed in the heating step has a technical feature that it can be replaced with butylene glycol.

In the method for preparing a composition for unsupervised wet wipes containing a component for inhibiting the growth of microorganisms according to the present invention, the complex extract gradually added in the stirring step may be purified water, rooibos leaf extract, oat leaf extract, aloe vera leaf extract , Olive leaf extract, green tea extract, isopentyldiol, and 1,2-hexanediol.

It is another object of the present invention to provide a composition for a whiteness-free wet tissue containing a component for inhibiting microbial propagation through the solution of the above problems and a method for producing the same, It is effective.

In addition, the present invention not only has high bactericidal activity, but also inhibits the propagation of microorganisms and prevents corruption. However, the present invention can also be used with confidence that residual water remains in infants, women, sensitive oral tissues and skin.

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a flow chart of a method for producing a composition for a no-opaque wet tissue containing a component for inhibiting microbial propagation according to the present invention;
2 is a flow chart of a skin irritation test of a composition for a no-opaque wet tissue containing a component inhibiting microbial propagation according to the present invention,
3 is a photograph showing the application of the invention according to Fig. 2 to a Finn chamber.

The following detailed description of the invention refers to the accompanying drawings, which illustrate, by way of illustration, specific embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention. It should be understood that the various embodiments of the present invention are different, but need not be mutually exclusive. For example, certain features, structures, and characteristics described herein may be implemented in other embodiments without departing from the spirit and scope of the invention in connection with one embodiment. It should also be understood that the position or arrangement of individual components within each disclosed embodiment may be varied without departing from the spirit and scope of the present invention. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the invention is to be limited only by the appended claims, along with the full scope of equivalents to which such claims are entitled. In the drawings, like reference numerals refer to the same or similar functions throughout the several views.

FIG. 1 is a flow chart of a method for preparing a composition for a no-opaque anti-wetting tissue containing a component for inhibiting microbial propagation according to the present invention, and FIG. 2 is a cross- Fig. 3 is a photograph showing application of the present invention according to Fig. 2 to a Finn chamber. Fig.

Hereinafter, the present invention will be described in detail with reference to examples. However, these examples are intended to further illustrate the present invention, and the scope of the present invention is not limited to these examples.

Among the compositions of the present invention, butylene glycol is contained in wine, soil yeast, corn oil, sunflower seed oil, etc., and is in the form of a colorless viscous liquid.

Butyleneglycol is widely used as a raw material for moisturizing agent, fragrance, skin conditioner and the like because it prevents deposition of melinin pigment on the skin, suppresses stain and freckle formation, and is excellent in moisturizing effect.

Isopentyldiol is a glycol-based environmentally friendly additive that can be used instead of butylene glycol, and acts as a solvent and solvent. It is a binder for colorless odorless vkdnej products and is often used in combination with certain raw materials.

Propanediol is a component extracted from corn, also called propylene glycol, a colorless hygroscopic liquid with no irritation and no toxicity.

It is used as a solvent and solvent because it helps to stabilize emulsification of hard-to-mix materials. It is excellent in preservative effect, but it can stimulate eyes and lungs. Should be.

Caprylhydroxamic Acid is used as a base horn component of coconut oil in place of a preservative such as paraben, and is an organic compound with high safety and high pH.

The main efficacy of caprylic hydroxamic acid is to stabilize the product by blocking the activity of the metal ion, which is highly likely to be incorporated in the production of cosmetics, and to prevent the degradation of the product by inhibiting the growth of microorganisms.

Octyldodeceth-16 is a polyethylene glycol ether of octyldodecanol, which is an addition polymerization of ethylene oxide to 2-octyldodecyl alcohol.

Octyldodecanol polymerized on octyldodeces-16 is a nonionic surfactant and emulsifier that is a natural component that helps skin's affinity with other active ingredients to be absorbed by the skin and has high safety.

1,2-Hexanediol is also referred to as 1,2-dihydroxyhexane. Because 1,2-hexanediol is a surfactant structure having both a hydrophobic group and a hydrophilic group, it is mixed with oil and water and used as an emulsifier , Solvent, preservative, antibacterial, and moisturizing, and is widely used as an antiseptic substitute.

In addition, it is used for manufacturing cosmetics because it prevents oxidation and is highly compatible.

 Ethylhexylglycerin is soluble in Glycoll and ethanol. It acts as a solvent to dissolve other ingredients and is applicable to various cosmetics such as water-soluble emulsion, lotion, gel and so on.

Among the complex extracts of the present invention, oat kelnel extract is also called oatmeal extract, and oatmeal is a moisturizing ingredient which has a dry, dull skin softening effect and an elasticity-enhancing effect.

< Example  1 > Preparation of composition

0.15 to 0.40 g of isopentyldiol and 0.25 to 0.4 g of propanediol are mixed with 99 g of purified water, and 0.12 to 0.25 g of caprylhydroxamic acid is mixed and heated to 40 to 60 캜.

Then, 0.01 to 0.08 g of octyldodeces-16 is dissolved in the heated mixture.

Thereafter, 0.15 to 0.4 g of 1,2-hexanediol and 0.1 to 0.2 g of ethylhexyl glycerin are mixed and introduced into the mixture, and the mixture is cooled to 25 ° C to 30 ° C.

Finally, 0.001 to 0.01 g of the complex extract is slowly added to the mixture, and the mixture is stirred for 30 minutes to 60 minutes.

The isopentyldiol of Example 1 above may be replaced with butylene glycol and the combined extract may be purified water, rooibos leaf extract, oat leaf extract, aloe vera leaf extract, wool rib leaf extract, green tea extract, isopentyldiol, And 2-hexanediol.

< Experimental Example  1> Skin irritation clinical test of the present invention

The first stage involves dermatologists and clinical practitioners interviewing and consulting to determine their condition.

In step 2, the test site of the clinical experimenter is wiped with 70% ethanol and dried. Then, 15 본 of the present invention is applied to the Finn chamber on the back of the clinician and fixed with a plaster.

In step 3, the patch is removed 24 hours after patch attachment, and 30 minutes after removal, test section is read by dermatologist.

In step 4, the dermatologist reads the test site 48 hours after patch attachment.

In step 5, the dermatologist reads the test site 72 hours after patch attachment.

The visual evaluation that dermatologists read is evaluated according to the criterion of the international contact dermatological research society and the criteria applying the safety evaluation guidelines of the American Cosmetics Association.

score Criteria 0(-) No signs of inflammation, normal skin 0.5 (±) Doubtful or slight reaction 1 (+) Slight erythema 2 (++) Moderate erythema with or without partial edema or papules 3 (+++) Moderate erythema with diffuse edema 4 (++++) intense erythema with diffuse edema with vesicles

Table 1 above is a guideline for a dermatologist to evaluate stability with a patch test skin irritation score system.

In step 6, the skin response score of the clinician is determined using Table 1, and the irritation index is calculated using the score.

The equation of irritation index is Σ {Irritation score at 24, 48 and 72 hr} / total number of observations.

In step 7, the average irritation index is calculated, and then the Draize Dermal Classification System and the Environmental Protection Agency (EPA) Standard Procedure Dermal Classification System are applied.

Stimulation index Irritability evaluation 0.00? &Lt; 0.02 No stimulation 0.02 < 0.25 Low stimulus 0.25? &Lt; 1.00 Light stimulus 1.00? 2.50 Moderate irritation 2.50? River stimulation

Table 2 above is a patch test skin irritation judgment table.

No. ID Gender Age No. ID Gender Age One 2555 F 22 18 2554 F 41 2 2556 F 22 19 2152 F 41 3 2420 F 23 20 2519 F 41 4 2557 F 29 21 1092 F 42 5 443 M 30 22 2153 F 44 6 2339 M 34 23 2551 F 44 7 2012 F 35 24 661 F 45 8 2347 F 36 25 1920 F 45 9 1526 F 36 26 2206 F 47 10 2319 F 36 27 752 F 47 11 2037 F 36 28 2242 F 48 12 1763 F 37 29 2162 F 48 13 2558 F 38 30 658 F 49 14 1713 F 38 31 2045 F 51 15 1285 F 39 32 2275 F 51 16 2241 F 39 33 1563 F 51 17 2380 F 40 34 2450 F 52

Table 3 summarizes the basic information of participants in clinical trials. The total number of subjects is 32 for male, 34 for total clinical trial, and the average age is 40 years.

ID 2016-1600-00-H-L BLANK 24H 48H 72H 24H 48H 72H 2555 0 0 0 0 0 0 2556 0 0 0 0 0 0 2420 0 0 0 0 0 0 2557 0 0 0 0 0 0 443 0 0 0 0 0 0 2339 0 0 0 0 0 0 2012 0 0 0 0 0 0 2347 0 0 0 0 0 0 1526 0 0 0 0 0 0 2319 0 0 0 0 0 0 2037 0 0 0 0 0 0 1763 0 0 0 0 0 0 2558 0 0 0 0 0 0 1713 0 0 0 0 0 0 1285 0 0 0 0 0 0 2241 0 0 0 0 0 0 2380 0 0 0 0 0 0 2554 0 0 0 0 0 0 2152 0 0 0 0 0 0 2519 0 0 0 0 0 0 1092 0 0 0 0 0 0 2153 0 0 0 0 0 0 2551 0 0 0 0 0 0 661 0 0 0 0 0 0 1920 0 0 0 0 0 0 2206 0 0 0 0 0 0 752 0 0 0 0 0 0 2242 0 0 0 0 0 0 2162 0 0 0 0 0 0 658 0 0 0 0 0 0 2045 0 0 0 0 0 0 2275 0 0 0 0 0 0 1563 0 0 0 0 0 0 2450 0 0 0 0 0 0 Irritation index / judgment 0 / No stimulation 0 / No stimulation

Table 4 shows the result of patch test for skin irritation to 34 clinical practitioners. The patch test was conducted using the present invention, and skin patches were performed at 30 minutes, 24 hours, 48 hours, and 72 hours after patch removal, As a result of the dermatologist's judgment as to whether or not the stimulation was performed, the skin irritation degree of the clinical practitioner was 0, indicating that the present invention is a non-irritating substance without irritation to the skin.

< Experimental Example  2> Buoyancy  Test

In the method of Experimental Example 2, a solution obtained by centrifuging (3000 rpm, 10 minutes) a raw material serving as a preservative in the present invention was used as a test solution. Escherichia coll ATCC 8739, Staphylococcus aureus ATCC 6538, Pseudomonas aeruginosa ATCC 9027, Candida albicans ATCC, Aspergillus niger ATCC 16404, and the test method is the 16. preservative test method of the Korean Pharmacopoeia 11th revision.

Test result Test Items unit Sample classification Results Test Methods Conservation test (E. coli) CFU / mL Early 1.3 x 10 ⁵






Korea Pharmacopeia
Eleventh Revision






Conservation test (E. coli) CFU / mL After 14 days &Lt; 10 (99.9% or more) Conservation test (E. coli) CFU / mL After 28 days &Lt; 10 (99.9% or more) Retention test (S. aureus) CFU / mL Early 5.5 × 10 ⁵ Retention test (S. aureus) CFU / mL After 14 days &Lt; 10 (99.9% or more) Retention test (S. aureus) CFU / mL After 28 days &Lt; 10 (99.9% or more) Conservation test (P.aeruginosa) CFU / mL Early 2.5 x 10 ⁵ Conservation test (P.aeruginosa) CFU / mL After 14 days &Lt; 10 (99.9% or more) Conservation test (P.aeruginosa) CFU / mL After 28 days &Lt; 10 (99.9% or more) Conservation test (C.albicans) CFU / mL Early 1.0 × 10 ⁵ Conservation test (C.albicans) CFU / mL After 14 days &Lt; 10 (99.9% or more) Conservation test (C.albicans) CFU / mL After 28 days &Lt; 10 (99.9% or more) Conservation test (A. niger) CFU / mL Early 1.6 × 10 ⁵ Conservation test (A. niger) CFU / mL After 14 days &Lt; 10 (99.9% or more) Conservation test (A. niger) CFU / mL After 28 days &Lt; 10 (99.9% or more)

Table 5 is a table showing the experimental results of Experimental Example 2, which shows that the test solution was preserved at 99.9% or more after 14 days and 28 days, compared with the initial values. In other words, it can be confirmed that the preservative function of the ingredient serving as a preservative in the present invention is certain.

< Experimental Example  3> The microbial test of the present invention

For the microorganism test of wet tissue, take 1 mL of sample / 9 mL of modified lectin liquid medium, accurately take about 3 mL of the vortex mixed solution for 60 seconds at room temperature, take 1.0 mL of methanol standard and add 1.0 L of water.

Take 0.3 mL, 0.5 mL, 1 mL, 2 mL, and 4 mL of this solution, and water is added to this classified solution to make 100 mL of the standard solution.

Test each specimen and standard solution according to the operating conditions by gas chromatograph-headspace method.

<Operating Conditions>

end. Gas chromatograph (1: 10 split ratio)

 ① Distillation method: Take about 10 mL of the sample accurately and put in a distillation flask, add 10 mL of water, 2 g of sodium chloride, 1 drop of silicone oil and 10 mL of ethanol without methanol, homogenize by ultrasonic and distill to obtain 15 mL of emulsion.

Add ethanol, which does not contain methanol, to this solution to make 50 mL, and use this solution as the sample solution after filtration.

Separately, take 2.0 mL of methanol accurately and add ethanol to make exactly 1 L. Take exactly 1.25 mL, 2.5 mL, 5 mL, 10 mL, and 20 mL of this solution and add methanol without methanol to make 50 mL. Standard solution.

Each standard and test solution is tested according to the following operating conditions.

 ② Dilution method: Take approximately 10 mL of the sample, add 10 mL of methanol-free ethanol, homogenize by ultrasonication, add ethanol with no methanol to make 50 mL, and filter it as the sample solution.

Separately, take 2.0 mL of methanol accurately and add ethanol to make exactly 1 L. Take exactly 1.25 mL, 2.5 mL, 5 mL, 10 mL, and 20 mL of this solution and add methanol without methanol to make 50 mL. Standard solution.

Each standard and test solution is tested according to the following operating conditions.

 ③ Depending on the type of sample, either distillation method or dilution method can be selected.

I. Headspace

The vial volume was 20 mL, the injection volume (loop) was 1 mL, the vial equilibrium temperature was 70 캜, the loop temperature was 80 캜, the injection line temperature was 90 캜, the vial equilibration time was 10 min, the vial purge time was 0.5 min, Min, the loop equilibration time is 0.1 min, and the injection time is 0.5 min.

Test result Test Items unit Sample classification Results Test Methods Total number of aerobic live bacteria (number of bacteria) Dogs / mL - <10 Food and Drug Administration
No. 2016-74 Total number of aerobic bacteria (number of fungi) Dogs / mL - <10

Table 6 is a table showing the test results of the microbial test. As a result, it is predicted that the effect of the preservative agent of the present invention is excellent because the test result shows that the value is lower than the reference value of cosmetics and fecal materials.

< Experimental Example  4> Oral toxicity test of the present invention

In order to evaluate the toxicity of the present invention in single oral administration, 21 male rats and 21 female rats of Crl: CD (SD), Rat SPF species of 6 weeks old were used.

The present invention was applied to sterilized distilled water (injection water) of the present invention at a concentration of 50 mg / mL, 100 mg / mL and 200 mg / mL, and a syringe equipped with a sonde for oral administration to each experimental animal The test substance prepared in the stomach and the control sterilized distilled water are forcedly administered once.

After the administration, the day of administration was observed at 0.5, 1, 2, 3, and 4 hours, followed by observation of the experimental animals for 14 days, and the appearance of the surviving animal was observed at day 14, The organ is examined.

Grooup Dose (mg / kg B.W.) Sex Number of animals Climical signs G1 0 M 5 Normal F 5 Normal G2 0 M 5 Normal F 5 Normal G3 0 M 5 Normal F 5 Normal G4 0 M 5 Normal F 5 Normal

As a result of the oral toxicity test of the present invention, deaths and abnormal symptoms due to the administration of the test substance during the experimental period were not observed, and the body weight change of the experimental animals was also observed in the test substance administration group and the excipient Normal weight gain was observed in the control group.

That is, since no gross abnormality was observed in major organs of all individuals, the present invention shows that the composition is free of toxicity and can be used for sensitive and fragile skin.

While the present invention has been described in connection with what is presently considered to be practical exemplary embodiments, it is to be understood that the invention is not limited to the disclosed embodiments, but, on the contrary, And such variations and modifications are intended to fall within the scope of the appended claims.

Claims (6)

0.15 to 0.4 part by weight of isopentyldiol, 0.25 to 0.4 part by weight of propanediol, 0.12 to 0.25 part by weight of caprylhydroxamic acid, 0.01 to 0.08 part by weight of octyldodeceth-16, 0.15 to 0.4 part by weight of hexanediol, 0.1 to 0.2 part by weight of ethylhexyl glycerin, and 0.001 to 0.01 part by weight of a combined extract, wherein the composition contains a microbial proliferation inhibiting component. The method according to claim 1,
Wherein the isopentyldiol can be replaced by butylene glycol. 2. The composition of claim 1, wherein the isopentyldiol is a butylene glycol. The method according to claim 1,
Wherein the complex extract comprises at least one of purified water, rooibos leaf extract, oat leaf extract, aloe vera leaf extract, wool rib leaf extract, green tea extract, isopentyl diol and 1,2-hexanediol. Wherein the composition contains a component that inhibits the growth of the wet tissue. A heating step of mixing 0.15 to 0.40 part by weight of isopentyldiol and 0.25 to 0.4 part by weight of propanediol with 0.12 to 0.25 part by weight of caprylic hydroxamic acid based on 99 parts by weight of purified water and heating the mixture to 40 to 60 캜;
Adding 0.01 to 0.08 part by weight of octyldodeceth-16 dissolved in the mixture heated in the heating step;
0.15 to 0.4 parts by weight of 1,2-hexanediol and 0.1 to 0.2 parts by weight of ethylhexyl glycerin are added to the mixture, and the mixture is cooled to 25 to 30 DEG C; And
And a stirring step of slowly adding 0.001 to 0.01 part by weight of the complex extract to the mixture after the cooling step and stirring the mixture for 30 minutes to 60 minutes. &Lt; / RTI &gt; 5. The method of claim 4,
Wherein the isopentyldiol mixed in the heating step can be replaced with butylene glycol. The method of claim 1, wherein the isopentyldiol is a diol. 5. The method of claim 4,
The complex extract gradually injected in the stirring step may contain at least one of purified water, rooibos leaf extract, oat leaf extract, aloe vera leaf extract, wool rib leaf extract, green tea extract, isopentyl diol and 1,2- The method of claim 1, wherein the microbial growth inhibitor is a compound of the formula (I).

Images